I made a video. Please keep sharing. I need this to go viral for our case to the U.S. FDA

This. Thanks.

The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering
sciencedirect.com/science/articl…

More from Dr. Shivaani Kummar on treatment options for desmoid tumors ⤵️

#RareDiseaseDay2024

'Desmoid tumors can result in significant impact on functioning and quality of life of patients.'

- Dr. Shivaani Kummar, who conducted the Phase 2 clinical trial study for the drug nirogacestat (a treatment of desmoid tumors): spr.ly/6016Vy7wm

Wow! Yes!

✅Improved overall survival
✅Improved compliance to clinical practice guidelines
✅📈 pre-surgery biopsies
✅📈 pre-surgery presentation at the NETSARC MDTB
✅📈 R0 resection on first surgery
✅📉R2 resection

2/2

The #1 cause of mortality in people with NF1 = tx-resistant MPNST #sarcoma . Arising within benign PN, MPNST are difficult to dx w/ delays resulting in incurable dz. We show that #cfDNA fragmentomics distinguishes MPNST's pre-malignant state, enabling early intervention! 🧵

#Postdoc position available on #sarcoma #Immunity at Molecular Pharmacology of Istituto Tumori - if interested please contact [email protected]

Health insurers when you tell them the patient is having an urgent medical need

Wow. I'm livid and shaking after the most aggressively obstructionist 'peer to peer' auth appeal I've ever had. For a CT on a pt with an intracardiac sarcoma!!!
#P2Phell #ourhealthcaresystemisfailingpatients #priorauth
Carelon for PacificSource - despicable practices.

Advanced Practice Provider Hematology/Oncology Fellowship

The program is designed for:

* ️Nurse practitioners and PAs seeking clinical experience in Hem/Onc
* APPs with no oncology background looking to transition to specialty care

Apply today: spr.ly/6011RzHKF

.OHSU News attracted a record $595.9 million in research funding during its 2023 fiscal year, supporting countless discoveries related to human health.

Of that funding, OHSU Knight Cancer Institute received $126.3 million!

#OHSUResearch : spr.ly/6014Rpv62

#pausingbeforeknocking

Delighted to share the stage with colleagues on behalf of everyone working to #endcancer as we know it in Oregon and beyond.

#OHSUsarcoma had fun shooting each other (with lasers only!) and drinking local beer (yum, pFriem) at our research group's end of the year party at King Pin's.

PS Team Davis beat Team Ryan! 😉🥳 Turns out Amber has skilz.

Osteosarcoma survivor carves a new path forward news.ohsu.edu/2023/12/07/ost…

So proud of Rebecca!
(and check out that awesome photo of gorgeous Oregon!)

#osteosarcoma The Osteosarcoma Institute SARC MIB Agents Osteosarcoma Alliance Sam Day Foundation Challenged Athletes Foundation

From the latest issue—
Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent #Osteosarcoma , by Michael Kinnaman, MD MS et al.
bit.ly/3Gmw7V9
Memorial Sloan Kettering Cancer Center

Keratin expression does not necessarily indicate carcinoma.

Some sarcomas, such as this desmoplastic small round cell tumor (DSRCT), show extensive keratin immunoreactivity. Important to consider sarcomas in the differential diagnosis for keratin-positive tumors.

#BSTpath